36092711|t|Olaparib, a PARP-1 inhibitor, protects retinal cells from ocular hypertension-associated oxidative damage.
36092711|a|Glaucoma is the most common cause of irreversible blindness worldwide. Elevated intraocular pressure (IOP) and relative hypoxia in the retina stimulate the production of reactive oxygen species (ROS), which, in turn, puts the retina and optic nerve under chronic oxidative stress. Emerging evidence has shown that oxidative stress can trigger PARP-1 overactivation, mitochondrial-associated endoplasmic reticulum membrane (MAM) dysregulation, and NLRP3 activation. Oxidative damage can trigger inflammasome activation, and NLRP3 is the only inflammasome associated with MAM dysregulation. In addition, multiple transcription factors are located on the MAM. This study aimed to investigate the protective effects and underlying mechanisms of a PARP-1 inhibitor (olaparib) against chronic ocular hypertension-associated retinal cell damage. We also mimicked hypoxic stimulation of a retinal precursor cell line by exposing the cells to 0.2% O2 in vitro. We discovered that chronic ocular hypertension (COH) induces oxidative damage and MAM dysregulation in the retinal ganglion cells (RGCs). The protein levels of cleaved-PARP and NLRP3 were upregulated in the retinas of the COH rats. Olaparib, a PARP-1 inhibitor, alleviated COH-induced RGC loss, retinal morphological alterations, and photopic negative response amplitude reduction. Olaparib also relieved hypoxic stimulation-induced loss of cell viability and MAM dysregulation. Additionally, some indicators of mitochondrial performance, such as reactive oxygen species accumulation, mitochondrial Ca2+ influx, and mitochondrial membrane potential collapse, decreased after olaparib treatment. Olaparib attenuated the hypoxia-induced upregulation of NLRP3 protein levels as well as the phosphorylation of ERK1/2 and histone H2A.X. These results suggest that olaparib protects RGCs from chronic intraocular pressure elevation in vivo and alleviates the abnormal MAM dysregulation and mitochondrial dysfunction caused by hypoxia in vitro. This protection may be achieved by inhibiting PARP-1 overactivation, NLRP3 upregulation, and phosphorylation of ERK1/2.
36092711	0	8	Olaparib	Chemical	MESH:C531550
36092711	12	18	PARP-1	Gene	25591
36092711	58	77	ocular hypertension	Disease	MESH:D009798
36092711	107	115	Glaucoma	Disease	MESH:D005901
36092711	157	166	blindness	Disease	MESH:D001766
36092711	227	234	hypoxia	Disease	MESH:D000860
36092711	277	300	reactive oxygen species	Chemical	MESH:D017382
36092711	302	305	ROS	Chemical	MESH:D017382
36092711	450	456	PARP-1	Gene	25591
36092711	473	509	mitochondrial-associated endoplasmic	Disease	MESH:D028361
36092711	554	559	NLRP3	Gene	287362
36092711	630	635	NLRP3	Gene	287362
36092711	677	694	MAM dysregulation	Disease	MESH:D015433
36092711	850	856	PARP-1	Gene	25591
36092711	868	876	olaparib	Chemical	MESH:C531550
36092711	886	913	chronic ocular hypertension	Disease	MESH:D009798
36092711	925	944	retinal cell damage	Disease	MESH:D012164
36092711	963	970	hypoxic	Disease	MESH:D002534
36092711	1046	1048	O2	Chemical	-
36092711	1078	1105	chronic ocular hypertension	Disease	MESH:D009798
36092711	1107	1110	COH	Disease	MESH:D009798
36092711	1141	1158	MAM dysregulation	Disease	MESH:D015433
36092711	1236	1241	NLRP3	Gene	287362
36092711	1281	1284	COH	Disease	MESH:D009798
36092711	1285	1289	rats	Species	10116
36092711	1291	1299	Olaparib	Chemical	MESH:C531550
36092711	1303	1309	PARP-1	Gene	25591
36092711	1332	1335	COH	Disease	MESH:D009798
36092711	1344	1352	RGC loss	Disease	MESH:D016388
36092711	1354	1387	retinal morphological alterations	Disease	MESH:D012173
36092711	1441	1449	Olaparib	Chemical	MESH:C531550
36092711	1464	1471	hypoxic	Disease	MESH:D002534
36092711	1519	1536	MAM dysregulation	Disease	MESH:D015433
36092711	1606	1629	reactive oxygen species	Chemical	MESH:D017382
36092711	1658	1662	Ca2+	Chemical	-
36092711	1734	1742	olaparib	Chemical	MESH:C531550
36092711	1754	1762	Olaparib	Chemical	MESH:C531550
36092711	1778	1785	hypoxia	Disease	MESH:D000860
36092711	1810	1815	NLRP3	Gene	287362
36092711	1865	1871	ERK1/2	Gene	50689;116590
36092711	1918	1926	olaparib	Chemical	MESH:C531550
36092711	2021	2038	MAM dysregulation	Disease	MESH:D015433
36092711	2043	2068	mitochondrial dysfunction	Disease	MESH:D028361
36092711	2079	2086	hypoxia	Disease	MESH:D000860
36092711	2143	2149	PARP-1	Gene	25591
36092711	2166	2171	NLRP3	Gene	287362
36092711	2209	2215	ERK1/2	Gene	50689;116590
36092711	Negative_Correlation	MESH:C531550	MESH:D016388
36092711	Negative_Correlation	MESH:C531550	MESH:D002534
36092711	Negative_Correlation	MESH:C531550	287362
36092711	Association	MESH:D000860	50689
36092711	Negative_Correlation	MESH:C531550	MESH:D012173
36092711	Association	MESH:D015433	287362
36092711	Negative_Correlation	MESH:C531550	MESH:D015433
36092711	Negative_Correlation	MESH:C531550	116590
36092711	Negative_Correlation	MESH:C531550	MESH:D009798
36092711	Negative_Correlation	MESH:C531550	MESH:D017382
36092711	Positive_Correlation	MESH:D000860	287362
36092711	Negative_Correlation	MESH:C531550	MESH:D000860
36092711	Positive_Correlation	MESH:D009798	287362
36092711	Negative_Correlation	MESH:C531550	MESH:D012164
36092711	Association	MESH:D000860	116590
36092711	Positive_Correlation	MESH:D017382	MESH:D000860
36092711	Negative_Correlation	MESH:C531550	25591
36092711	Negative_Correlation	MESH:C531550	50689
36092711	Negative_Correlation	MESH:C531550	MESH:D028361

